Skip to main content
S 1681 116th Congress Senate Health Drug safety, medical device, and laboratory regulation Government information and archives Health personnel Immunology and vaccination Licensing and registrations Manufacturing Medical education Medicare Prescription drugs

Advancing Education on Biosimilars Act of 2019

Introduced: May 23, 2019 See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 9 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 18, 2020
Held at the desk.
Dec 18, 2020
Received in the House.
Dec 18, 2020
Message on Senate action sent to the House.
Dec 17, 2020
Passed Senate with an amendment by Unanimous Consent. (text of amendment in the nature of a substitute: CR S7643)
Dec 17, 2020
Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.
Dec 17, 2020
Measure laid before Senate by unanimous consent. (consideration: CR S7642-7643)
Dec 17, 2020
Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.
May 23, 2019
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
May 23, 2019
Introduced in Senate
 Amendments to this bill 1

Amendments propose changes to this bill. Members vote on amendments separately before the final bill vote. An agreed amendment becomes part of the bill; a failed amendment does not.

1 agreed to

AmendmentSponsorPurposeStatusLatest action
SAMDT 2,716 — In the nature of a substitute. Agreed to Dec 17, 2020
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Advancing Education on Biosimilars Act of 2019

This bill addresses education for the public and for health care providers regarding biosimilars. (Biosimilars are biological products approved by the Food and Drug Administration based on their similarity to an already approved biological product.)

The bill requires the Department of Health and Human Services (HHS) to create a website for educational materials on the meaning and use of biosimilars and interchangeable biological products.

HHS must also develop or improve continuing medical education programs for health care providers regarding biosimilars.

What's happening now December 18, 2020

Held at the desk.

 Bill text 2 versions

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 1
All 1 Democratic 1
D
Hassan, Margaret Wood
New Hampshire · May 23, 2019
Cite this page click to expand
APA
U.S. Congress. (2026). S. 1681: Advancing Education on Biosimilars Act of 2020. 116th Congress. Open America. https://openamerica.io/bill/116-S-1681/
MLA
"S. 1681: Advancing Education on Biosimilars Act of 2020." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-S-1681/.
Bluebook (legal)
S. 1681, 116th Cong. (2026), https://openamerica.io/bill/116-S-1681/.
Markdown link
[S. 1681: Advancing Education on Biosimilars Act of 2020](https://openamerica.io/bill/116-S-1681/)
Report a problem